Linezolid Trough Concentrations Correlate with Mitochondrial Toxicity-Related Adverse Events in the Treatment of Chronic Extensively Drug-Resistant Tuberculosis

Taeksun Song, Myungsun Lee, Han Seung Jeon, Yumi Park, Lori E. Dodd, Véronique Dartois, Dean Follman, Jing Wang, Ying Cai, Lisa C. Goldfeder, Kenneth N. Olivier, Yingda Xie, Laura E. Via, Sang Nae Cho, Clifton E. Barry, Ray Y. Chen

Research output: Contribution to journalArticlepeer-review

51 Citations (Scopus)

Abstract

Long-term linezolid use is limited by mitochondrial toxicity-associated adverse events (AEs). Within a prospective, randomized controlled trial of linezolid to treat chronic extensively drug-resistant tuberculosis, we serially monitored the translational competence of mitochondria isolated from peripheral blood of participants by determining the cytochrome c oxidase/citrate synthase activity ratio. We compared this ratio with AEs associated with mitochondrial dysfunction. Linezolid trough concentrations were determined for 38 participants at both 600 mg and 300 mg doses. Those on 600 mg had a significantly higher risk of AE than those on 300 mg (HR 3·10, 95% CI 1·23-7 · 86). Mean mitochondrial function levels were significantly higher in patients before starting linezolid compared to their concentrations on 300 mg (P = 0·004) or 600 mg (P < 0·0001). Increasing mean linezolid trough concentrations were associated with lower mitochondrial function levels (Spearman's ρ = -0.48; P = 0.005). Mitochondrial toxicity risk increased with increasing linezolid trough concentrations, with all patients with mean linezolid trough > 2 μg/ml developing an AE related to mitochondrial toxicity, whether on 300 mg or 600 mg. Therapeutic drug monitoring may be useful to prevent the development of mitochondrial toxicity associated with long-term linezolid use.

Original languageEnglish
Pages (from-to)1627-1633
Number of pages7
JournalEBioMedicine
Volume2
Issue number11
DOIs
Publication statusPublished - 2015 Nov 1

Bibliographical note

Funding Information:
This project has been funded in whole or in part with federal funds from the Intramural Research Programs, National Institute of Allergy and Infectious Diseases and National Heart, Lung, and Blood Institute, National Institutes of Health; the National Cancer Institute, National Institutes of Health , under contract no. HHSN261200800001E ; and by the Ministry of Health and Welfare, Republic of Korea . The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

Publisher Copyright:
© 2015.

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Linezolid Trough Concentrations Correlate with Mitochondrial Toxicity-Related Adverse Events in the Treatment of Chronic Extensively Drug-Resistant Tuberculosis'. Together they form a unique fingerprint.

Cite this